Bausch Health Companies (BHC) Cash & Equivalents (2009 - 2026)

Bausch Health Companies has disclosed Cash & Equivalents across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.3 billion, up 14.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 14.55% YoY), and the FY2025 annual result was $1.3 billion, up 10.84% from the prior year.
• Cash & Equivalents came in at $1.3 billion for Q1 2026 at Bausch Health Companies, down from $1.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q2 2025 to a low of $486.0 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $760.0 million (2023), against an average of $927.5 million.
• Across the five-year window, Cash & Equivalents slumped 58.53% in 2023 and surged 190.25% in 2025, its largest moves.
• Bausch Health Companies' Cash & Equivalents stood at $564.0 million in 2022, then soared by 67.91% to $947.0 million in 2023, then grew by 24.71% to $1.2 billion in 2024, then climbed by 10.84% to $1.3 billion in 2025, then fell by 0.76% to $1.3 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.